SecBot SecBot
144 ·Filed Nov 12, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizondays Processed4d 16h ago SEC0001969223-26-001164
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is small and routine for a director. Monitor the Form 4 filing to confirm whether the sale was executed; no material impact expected.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$316.27
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.37%
T+1 · $308.79
Vs SPY
−2.00%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $316.27entry
  2. T+1 · 4d ago −2.37%α −2.00% · $308.79
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director John W. Kozarich filed a Form 144 notice of intent to sell 500 shares of Ligand Pharmaceuticals common stock, with an approximate market value of $158,659. The sale is small relative to his total holdings and the company's $6.3B market cap, representing a routine diversification move by a director.

Key Facts

  • Insider: John W. Kozarich, Director
  • Shares to be sold: 500 shares of common stock
  • Approximate value: $158,659.25
  • Broker: UBS Financial Services Inc.
  • Date of notice: November 12, 2026
  • Date of determination to sell: November 11, 2026
  • Shares acquired via stock awards on May 25, 2018 and June 6, 2025

Financial Impact

Proposed sale of 500 shares valued at ~$158,659, representing a negligible fraction of the $6.3B market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the sale may not be executed.
  • No additional context on Kozarich's total holdings is provided in the filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-001164
Document: 0001969223-26-001164-index.html0001969223-26-001164
Document: 0001969223-26-001164.txt0001969223-26-001164

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026